Literature DB >> 33776473

Using Thromboelastography to Predict Blood Loss After Off-Pump Coronary Artery Bypass Grafting.

Yu Liu1, Wen-Li Zhang1, Ji-Qiang Bu1, Jian-Jun Gu1, Yong-Quan Sun1, Hong-Zhan Cui1, Da-Wei Wang2, Zi-Ying Chen1.   

Abstract

OBJECTIVE: This study aims to investigate the value of thromboelastography (TEG) in predicting blood loss, and its relationship with blood transfusion demand, during the perioperative period in off-pump coronary artery bypass grafting (OPCABG).
METHODS: The data of 398 patients undergoing OPCABG were retrospectively analyzed. Blood was drawn before anesthesia induction (T1) and at 10 minutes after heparin neutralization (T2) for further TEG detection. The patients were divided into two groups based on the results at T2: a TEG normal group and a TEG abnormal group. Logistic regression analysis was used to predict the related factors contributing to the significant increase in perioperative blood loss (more than 20% of the estimated blood volume).
RESULTS: There were 277 (69.6%) patients in the TEG normal group and 121 (30.4%) in the TEG abnormal group. Compared with the TEG normal group, the volume of blood loss, red blood cell count, and volume of plasma transfusion in the TEG abnormal group significantly increased within 24 hours after surgery. The results of the logistic regression analysis identified the use of clopidogrel, platelet count at T2, fibrinogen level at T2, and abnormality in TEG value as independent predictors for the significant increase in perioperative blood loss (P < 0.001).
CONCLUSION: The abnormality in TEG value after heparin neutralization is correlated with massive hemorrhage and blood transfusion during the perioperative period in OPCABG. TEG detection can assist in clinical treatment and reduce the volume of blood lost in a hemorrhage and the volume of blood required in a transfusion during OPCABG.
© 2021 Liu et al.

Entities:  

Keywords:  blood loss; blood transfusion; off-pump coronary artery bypass grafting; perioperative period; thromboelastography

Year:  2021        PMID: 33776473      PMCID: PMC7989370          DOI: 10.2147/IJGM.S291864

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  20 in total

1.  Safety of recombinant activated factor VII in randomized clinical trials.

Authors:  Marcel Levi; Jerrold H Levy; Henning Friis Andersen; David Truloff
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Thromboelastography in off-pump coronary artery bypass grafting.

Authors:  Sushil Kumar Singh; Vijayant Devenraj; Vivek Tewarson; Sarvesh Kumar; Dinesh Kaushal; Tulika Chandra
Journal:  Asian Cardiovasc Thorac Ann       Date:  2014-11-12

3.  Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial.

Authors:  Gregg W Stone; Tim C Clayton; Roxana Mehran; George Dangas; Helen Parise; Martin Fahy; Stuart J Pocock
Journal:  Am Heart J       Date:  2012-03       Impact factor: 4.749

4.  Validity of Thromboelastometry for Rapid Assessment of Fibrinogen Levels in Heparinized Samples During Cardiac Surgery: A Retrospective, Single-center, Observational Study.

Authors:  Hamish Mace; Nicholas Lightfoot; Stuart McCluskey; Rita Selby; Debashis Roy; Tarik Timoumi; Keyvan Karkouti
Journal:  J Cardiothorac Vasc Anesth       Date:  2015-05-05       Impact factor: 2.628

5.  Thromboelastometry-guided intraoperative haemostatic management reduces bleeding and red cell transfusion after paediatric cardiac surgery.

Authors:  Y Nakayama; Y Nakajima; K A Tanaka; D I Sessler; S Maeda; J Iida; S Ogawa; T Mizobe
Journal:  Br J Anaesth       Date:  2014-10-10       Impact factor: 9.166

6.  2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.

Authors:  Domenico Pagano; Milan Milojevic; Michael I Meesters; Umberto Benedetto; Daniel Bolliger; Christian von Heymann; Anders Jeppsson; Andreas Koster; Ruben L Osnabrugge; Marco Ranucci; Hanne Berg Ravn; Alexander B A Vonk; Alexander Wahba; Christa Boer
Journal:  Eur J Cardiothorac Surg       Date:  2018-01-01       Impact factor: 4.191

7.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983

8.  Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.

Authors:  Sibylle A Kozek-Langenecker; Aamer B Ahmed; Arash Afshari; Pierre Albaladejo; Cesar Aldecoa; Guidrius Barauskas; Edoardo De Robertis; David Faraoni; Daniela C Filipescu; Dietmar Fries; Thorsten Haas; Matthias Jacob; Marcus D Lancé; Juan V L Pitarch; Susan Mallett; Jens Meier; Zsolt L Molnar; Niels Rahe-Meyer; Charles M Samama; Jakob Stensballe; Philippe J F Van der Linden; Anne J Wikkelsø; Patrick Wouters; Piet Wyffels; Kai Zacharowski
Journal:  Eur J Anaesthesiol       Date:  2017-06       Impact factor: 4.330

9.  Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study.

Authors:  Koray Ak; Cemil S Isbir; Sermin Tetik; Nazan Atalan; Atike Tekeli; Maher Aljodi; Ali Civelek; Sinan Arsan
Journal:  J Card Surg       Date:  2009 Jul-Aug       Impact factor: 1.620

10.  Effect of thrombelastography on timing of coronary artery bypass grafting.

Authors:  Zhiyuan Yang; Zhouliang Xie; Xueliang Pei; Xiaoqiang Quan; Deguang Feng
Journal:  Exp Ther Med       Date:  2018-05-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.